慢性乙型肝炎患者血清铁调素和铁代谢指标及体外HBV转染Huh7细胞铁调素水平变化*

doi:10.3969/j.issn.1672-5069.2020.02.009

实用肝脏病杂志 ›› 2020, Vol. 23 ›› Issue (2): 183-186.doi: 10.3969/j.issn.1672-5069.2020.02.009

慢性乙型肝炎患者血清铁调素和铁代谢指标及体外HBV转染Huh7细胞铁调素水平变化^*

王兆飞, 管世鹤, 陈礼文, 王琴, 杨凯, 张浩, 候舒文, 潘正兰, 段元丽

230601 合肥市安徽医科大学第二附属医院检验科

收稿日期:2019-03-05 出版日期:2020-03-10 发布日期:2020-04-20
通讯作者: 管世鹤,E-mail:shiheguan@126.com
作者简介:王兆飞,男,28岁,硕士研究生,检验师。主要从事分子病毒与免疫学研究。E-mail:friwzf@163.com
基金资助:
安徽省科技厅重点研究与开发计划项目(编号:1804h08020236);安徽省高校自然科学研究项目(编号:KJ2018A0206);安徽医科大学第二附属医院首批“火花计划”科研项目(编号:2015hhjh06)

Changes ofserum hepcidin and iron metabolism index in patients with hepatitis B and in pC1.3 plasmid-transfected Huh7 cells in vitro

Wang Zhaofei, Guan Shihe, Chen Liwen, et al

Department of Cinical Laboratory, Second Hospital, Affiliated to Anhui Medical University, Hefei 230601, Anhui Province, China

Received:2019-03-05 Online:2020-03-10 Published:2020-04-20

摘要/Abstract

摘要： 目的探讨慢性乙型肝炎(CHB)患者血清铁调素(Hepc)和铁代谢指标的变化,并在体外观察HBV转染肿瘤细胞Hepc表达的变化。方法在71例CHB患者和24例健康体检者,采用ELISA法检测血清Hepc水平,使用全自动蛋白分析仪检测血清铁(SI)、铁蛋白(Ferr)和转铁蛋白(Tf)水平。使用电化学发光全自动免疫分析仪检测血清IL-6水平。构建HBV感染Huh7细胞模型,分别采用RT-qPCR和Western blot法检测细胞Hepc表达情况。结果与健康人比较,CHB组血清SI、Ferr、IL-6、丙氨酸氨基转移酶 (ALT)、天门冬氨酸氨基转移酶(AST)、血清总胆红素 (TBIL)水平均显著升高,Hepc、Tf和可溶性转铁蛋白受体(sTfR)、白蛋白(ALB)显著降低(P<0.05);转染细胞24 h,Hepc mRNA相对水平为(5.21±0.43),空白对照细胞的(0.73±0.14)显著升高(P<0.05),在转染48 h,细胞Hepc mRNA水平为(8.45±0.61),较空白对照的(1.16±0.17)显著升高(P<0.05);在质粒转染48 h后,细胞Hepc蛋白相对表达量为(0.78±0.08),较空白对照的(0.41±0.02)显著升高(P<0.05)。结论检测铁调素及其铁代谢相关指标有助于评估慢性乙型肝炎病情进展,适当予以铁调素或者其相应内源性激活剂针对性地治疗铁超载CHB患者,是否可应用于临床,值得期待。

关键词: 慢性乙型肝炎, 铁调素, 铁代谢, Huh7细胞

Abstract: Objective To investigate the changes of serum hepcidin and iron metabolism index in patients with hepatitis B and in pC1.3 plasmid containing HBV genome-transfected Huh7 cells in vitro. Method 71 patients with CHB and 24 healthy subjects were recruited in this study, and serum hepcidin, serum iron (SI), ferritin (Ferr), and transferrin (Tf) as well as IL-6 levels were detected. The HBV-infected Huh7 cells were constructed, and the expression of Hepc were detected by RT-PCR and Western blot, respectively. Result Serum SI, Ferr, IL-6, alanine aminotransferase (ALT), serum aspartate aminotransferase (AST), and serum total bilirubin (TBIL) levels were significantly elevated and serum Hepc, Tf, soluble transferrin receptor (sTfR), and albumin (ALB) levels were significantly decreased (P<0.05) in patients with CHB as compared to those in healthy persons (P<0.05); the relative levels of Hepc mRNA in HBV-transfected Huh7 cells at 24 h after transinfection was (5.21±0.43) , significantly higher than (0.73±0.14) in vacant plasmid-infected Huh7 cells (P<0.05), and at 48 h, it was (8.45±0.61), also significantly higher than (1.16±0.17) in the control (P<0.05); the relative expression of Hepc protein in HBV-transfected Huh7 cells at 48 h of plasmid transfection was (0.78±0.08), significantly higher than (0.41±0.02) in the vacant (P<0.05). Conclusion Detection of hepcidin and iron metabolism-related indicators might help to assess the progress of chronic hepatitis B, and an appropriate administration of hepcidin or its corresponding endogenous activators needs clinical trials.

Key words: Hepatitis B, Hepcidin, Iron metabolism, Huh7 cells

王兆飞, 管世鹤, 陈礼文, 王琴, 杨凯, 张浩, 候舒文, 潘正兰, 段元丽. 慢性乙型肝炎患者血清铁调素和铁代谢指标及体外HBV转染Huh7细胞铁调素水平变化^*[J]. 实用肝脏病杂志, 2020, 23(2): 183-186.

Wang Zhaofei, Guan Shihe, Chen Liwen, et al. Changes ofserum hepcidin and iron metabolism index in patients with hepatitis B and in pC1.3 plasmid-transfected Huh7 cells in vitro[J]. Journal of Practical Hepatology, 2020, 23(2): 183-186.

参考文献

[1] Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science, 2012, 338(6108):768.
[2] Zou D M , Sun W L . Relationship between hepatitis C virus infection and iron overload. Chin Med J,2017, 130(7):866.
[3] Foka P , Dimitriadis A , Karamichali E , et al. Alterations in the iron homeostasis network: A driving force for macrophage-mediated hepatitis C virus persistency. Virulence, 2016, 7(6):12.
[4] Gao YH , Wang JY, Liu PY. Iron metabolism disorders in patients with hepatitis B-related liver diseases. World J Clin Cases,2018,6(13):600-610.
[5] Lin D, Ding J, Liu J Y. Decreased serum hepcidin concentration correlates with brain iron deposition in patients with HBV-related cirrhosis. Plos One, 2013, 8(6):e65551.
[6] Yonal O, Akyuz F, DemiR K. Decreased prohepcidin levels in patients with HBV-related liver disease: relation with ferritin levels. Dig Dis Sci, 2010, 55(12):3548-3551.
[7] Akram A , Islam S M R , Munshi S U. Detection of hepatitis B virus DNA among chronic and potential occult HBV patients in resource-limited settings by loop-mediated isothermal amplification assay. J Viral Hepat, 2018[ahead of print] .
[8] 翁艳. 恩替卡韦联合硫普罗宁治疗慢性乙型肝炎患者肝功能及其肝纤维化指标的变化. 实用肝脏病杂志, 2018, 21(2): 212-215.
[9] Liaw Y F, Brunetto M R, Hadziyannis S. The natural history of chronic HBV infection and geographical differences. Antiviral Ther, 2010, 15(3):25-33.
[10] Armitage A E, Stacey A R, Giannoulatou E. Distinct patterns of hepcidin and iron regulation during HIV-1, HBV, and HCV infections. Proc Nat Acad Sci USA, 2014,111(33):12187-12192.
[11] Fung E, Nemeth E. Manipulation of the hepcidin pathway for therapeutic purposes. Haematologica, 2013, 98(11):1667-1676.
[12] Preza G C, Ruchala P, Pinon R. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. J Clin Invest, 2011,121(12):4880-4888.
[13] Poli M, Asperti M, Ruzzenenti P. Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front Pharmacol, 2014, 5(86):86.
[14] Beckebaum S, Herzer K, Bauhofer A, et al. Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis. Ann Transplant., 2018,23:789-801.
[15] Zhou YH. Treatment of Chronic Hepatitis B Infection, JAMA, 2018,320(11):1201.
[16] Lee T, Yang JJ, Eom J, et al. A single-center, single-blind study to evaluate the clinical sensitivity, specificity, and agreement between Elecsys Anti-HBc II and Elecsys Anti-HBc in a Korean population. J Clin Virol, 2018, 109:41-44.
[17] Zhang S, Guo H, Smith R. Dynamical analysis for a hepatitis B transmission model with immigration and infection age. Math Biosci Eng, 2018,15(6):1291-1313..
[18] Pandey A, Ezemenari S, Liaukovich M, et al. A Rare Case of Pembrolizumab-Induced Reactivation of Hepatitis B. Case Rep Oncol Med, 2018,2018:5985131.
[19] Katoonizadeh A, Motamed-Gorji N, Sharafkhah M, et al. Intra-familial Transmission of Chronic Hepatitis B Infection: A Large Population-Based Cohort Study in Northern Iran.Arch Iran Med, 2018,21(10):436-442.

慢性乙型肝炎患者血清铁调素和铁代谢指标及体外HBV转染Huh7细胞铁调素水平变化^*

Changes ofserum hepcidin and iron metabolism index in patients with hepatitis B and in pC1.3 plasmid-transfected Huh7 cells in vitro

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	周翠梅, 胡立芬, 李家斌, 储雪琴, 郜玉峰. 思维导图在慢性乙型肝炎患者管理中应用价值研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 187-190.
[2]	杨可芷, 陆伟, 黄丹, 李秀芬, 王雁冰, 周新兰, 丁蓉蓉, 张占卿. γ-谷氨酰转肽酶/胆碱酯酶比值预测慢性乙型肝炎患者肝纤维化程度的效能评价^*[J]. 实用肝脏病杂志, 2020, 23(1): 14-17.
[3]	叶细容, 吕志红, 江峰, 解育新. 两种超声弹性成像技术诊断慢性乙型肝炎患者肝纤维化价值比较^*[J]. 实用肝脏病杂志, 2020, 23(1): 18-21.
[4]	李永华, 孙延芬, 王佳佳, 李艳颖, 于收. 恩替卡韦联合苦参素治疗慢性乙型肝炎患者疗效及其对外周血辅助性T淋巴细胞的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 22-25.
[5]	丁俊琪, 张偲, 张彬. 聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎部分应答患者序贯替比夫定治疗疗效观察^*[J]. 实用肝脏病杂志, 2020, 23(1): 26-29.
[6]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[7]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[8]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[9]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[10]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[11]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[12]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[13]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[14]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[15]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.